gramicidin
Approved
Jul 3, 1968
Gramicidin, also called gramicidin D, is a mix of ionophoric antibiotics, gramicidin A, B and C, which make up about 80%, 5%, and 15% of the mix, respectively. Each has 2 isoforms, so the mix has 6 different types of gramicidin molecules. They can be extracted from Brevibacillus brevis soil bacteria. Gramicidins are linear peptides with 15 amino acids. This is in contrast to unrelated gramicidin S, which is a cyclic peptide. — Wikipedia
Clinical trial activity
4 trials · 3 clinical orgs · 9 marketing orgs
Earliest trial started Sep 1, 2022 (NCT05449392)
Timeline
1960s
- Jul 3, 1968
Earliest FDA Approval
- Jul 3, 1968
Monarch Pharmaceuticals — Marketing Organization
1990s
- Jan 31, 1996
Bausch & Lomb — Marketing Organization
2000s
- Oct 28, 2005
Amring Pharmaceticals — Marketing Organization
- Oct 28, 2005
Saptalis Pharmaceuticals — Marketing Organization
- Oct 28, 2005
Sciegen Pharmaceticals — Marketing Organization
Indications
Approved for
Mechanism of action
- Cell membraneDISRUPTING AGENT
Cell membrane disrupting agent
Combination products
neosporin
with neomycin, polymyxin b sulfate
Also known as neomycin and polymyxin b sulfates and gramicidin
Approval history
- approvedJul 3, 1968
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaGramicidin ↗
- NCATS5IE62321P4 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06859281 | Phase 1 | Dec 10, 2024 | Valenta Pharm JSC |
| NCT06857890 | Phase 1 | Dec 9, 2024 | Valenta Pharm JSC |
| NCT06843018 | Phase 2 | Nov 14, 2024 | Valenta Pharm JSC |
| NCT05449392 | Phase 1 | Sep 1, 2022 | Bill and Melinda Gates Foundation, Yale University |
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Valenta Pharm JSC | For profit | 3 | 3 | 2 | 2024 |
| Bill and Melinda Gates Foundation | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Yale University | Academic/Hospital | 1 | 1 | 1 | 2022 |
Marketing (9)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Amring Pharmaceticals | For profit | MKTG | Oct 28, 2005 |
| Bausch & Lomb | For profit | MKTG | Jan 31, 1996 |
| Dow Pharmaceutical Sciences | For profit | MKTG | — |
| Monarch Pharmaceuticals | For profit | MKTG | Jul 3, 1968 |
| Pharmafair | For profit | MKTG | — |
| Saptalis Pharmaceuticals | For profit | MKTG | Oct 28, 2005 |
| Sciegen Pharmaceticals | For profit | MKTG | Oct 28, 2005 |
| Watson Pharmaceuticals | For profit | MKTG | — |
| iPharma | For profit | MKTG | — |